Early Access — free while we kick the tires
EdgarHawk

CON Concentra Group Holdings Parent, Inc. Insider Trading

Latest: Director Sold $3.2M of Shares · May 2026
2 filings analyzed · Latest 2026-06-02
Insider buys
0
Insider sells
2
Unique insiders
1
Direction
Net selling
June 2026
2026-06-02
low
Robert A Ortenzio Sell
130,000 shares
$3,250,026
@ $25.00
Significance 4/10

Director Robert A Ortenzio sells 130,000 shares of CON at $25.00 for $3,250,026.00 under 10b5-1 plan.

Robert A Ortenzio, a director of Concentra Group Holdings Parent, Inc., sold 130,000 shares (130.0K shares) at $25.00 on 2026-06-01, reducing his holdings from 893,455 shares (893.5K shares) to 763,455 shares (763.5K shares), a -14.6% net change. This transaction is part of a pre-arranged 10b5-1 trading plan, meaning it was scheduled and not discretionary. The stock currently trades at $25.09, within its 52-week range of $18.54–$26.66. Concentra's fundamentals show solid underlying performance with Revenue of $569,555,000.00 (latest quarter), Net income of $50,488,000.00, annual revenue growth of +13.8%, and a P/E of 18.05. Since the sale was scheduled under a 10b5-1 plan rather than a discretionary choice, the transaction does not reflect a timing signal or conviction-driven decision by the insider.

May 2026
2026-05-11
medium
Robert A Ortenzio Sell
130,000 shares
$3,250,000
@ $25.00
Significance 5/10

Director Robert A Ortenzio sells 130,000 shares for $3.25M, his 13th open-market sale in 36 months.

Robert A Ortenzio, a member of the board, disposed of roughly 12.7% of his Concentra holdings in a single transaction valued at $3.25 million—his thirteenth open-market sale over the past three years and a continuation of a consistent pattern of selling without any offsetting purchases. The timing is notable: the stock trades just slightly below its 52-week high and has gained ground over the past month, creating a backdrop where insiders might be inclined to take profits. Ortenzio's prior twelve sales all resulted in the stock declining within 90 days, suggesting a strong track record of well-timed exits; this latest sale extends that pattern. The company remains profitable with solid revenue growth and is trading at a reasonable valuation multiple, so this sale does not appear to signal financial distress—rather, it reflects a director systematically reducing his stake in what appears to be a fundamentally sound business.

More Health Services companies

Get alerts for CON

Add CON to your watchlist and we'll email you when an insider files a Form 4 — with our AI's significance score and a plain-English read of what it means.

Sign up — free during early access